Home Cart Sign in  
Chemical Structure| 1231929-97-7 Chemical Structure| 1231929-97-7

Structure of Abemaciclib
CAS No.: 1231929-97-7

Chemical Structure| 1231929-97-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Abemaciclib is a selective CDK4/6 inhibitor with IC50 values of 2 nM for CDK4 and 10 nM for CDK6. Abemaciclib has antitumor effects and is used in research on HR+/HER2- breast cancer and other tumors.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Abemaciclib

CAS No. :1231929-97-7
Formula : C27H32F2N8
M.W : 506.59
SMILES Code : CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
MDL No. :MFCD22665744
InChI Key :UZWDCWONPYILKI-UHFFFAOYSA-N
Pubchem ID :46220502

Safety of Abemaciclib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Abemaciclib

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK4

    CDK4, IC50:2 nM

  • CDK6

    CDK6, IC50:10 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF7 500 nM 7 days To study the effect of Abemaciclib on chromatin accessibility in MCF7 cells, results showed that Abemaciclib induced widespread chromatin remodeling. PMC8115221
MDA-MB-453 500 nM 7 days To study the effect of Abemaciclib on chromatin accessibility in MDA-MB-453 cells, results showed that Abemaciclib induced widespread chromatin remodeling. PMC8115221
Human primary fibroblasts (BJ) 1 µM 8 days Abemaciclib induced cell cycle arrest, characterized by reduced RB phosphorylation, downregulation of E2F2, and increased p16 expression. Proliferation was not restored after drug withdrawal. PMC8922251
Human primary fibroblasts (WI38) 1 µM 8 days Abemaciclib induced cell cycle arrest, characterized by reduced proliferation, and proliferation was not restored after drug withdrawal. PMC8922251
A549 cells 10 µM 24 h To evaluate the inhibitory effect of Abemaciclib and P2shortA on the proliferation of A549 cells. Results showed that P2shortA significantly inhibited A549 cell proliferation at 5-10 µM, and exhibited a synergistic effect when combined with Abemaciclib. PMC7019173
H358 cells 10 µM 24 h To evaluate the inhibitory effect of Abemaciclib and P2shortA on the proliferation of H358 cells. Results showed that P2shortA significantly inhibited H358 cell proliferation at 5-10 µM, and exhibited a synergistic effect when combined with Abemaciclib. PMC7019173
PC9 cells 10 µM 24 h To evaluate the inhibitory effect of Abemaciclib and P2shortA on the proliferation of PC9 cells. Results showed that P2shortA significantly inhibited PC9 cell proliferation at 5-10 µM, and exhibited a synergistic effect when combined with Abemaciclib. PMC7019173
MCF7 0.1 μM to 20 μM 6 months To construct MCF7 cells resistant to Abemaciclib and observe the expression changes of PARP1 and p-YB-1. The results showed that with the increase of Abemaciclib concentration, the expression of PARP1 and p-YB-1 was significantly upregulated. PMC10687910
MCF7AR 50 μM To evaluate the resistance of MCF7AR cells to Abemaciclib and verify the expression levels of PARP1 and p-YB-1. The results showed that the IC50 of MCF7AR cells to Abemaciclib was significantly higher than that of MCF7 cells, and the expression of PARP1 and p-YB-1 was upregulated. PMC10687910
MCF7 cells 100 nM 24 h Abemaciclib significantly inhibited the kinase activity of CDK4 but had a weaker effect on CDK6. PMC8831444
MCF7 FAT1-loss cells 100 nM 24 h Abemaciclib significantly inhibited the kinase activity of CDK4 but had a weaker effect on CDK6. PMC8831444
HCC1428-LTED-AbemaR 250 nM 6-12 months To evaluate the anti-proliferative effect of Abemaciclib in CDK4/6 inhibitor-resistant cells. Results showed that Abemaciclib inhibited the growth of resistant cells in both short-term and long-term proliferation assays, although the extent of inhibition was reduced compared to sensitive cells. PMC6921513
MCF7-LTED-D538G-AbemaR 250 nM 6-10 months To evaluate the anti-proliferative effect of Abemaciclib in ESR1-mutant CDK4/6 inhibitor-resistant cells. Results showed that Abemaciclib inhibited the growth of resistant cells in both short-term and long-term proliferation assays, although the extent of inhibition was reduced compared to sensitive cells. PMC6921513
HER2+ breast cancer cell lines 2 µM 24 hours Evaluate the effect of Sitravatinib combined with CDK4/6 inhibitors on HER2+ breast cancer cells, showing lower sensitivity compared to TNBC cells. PMC11202171
TNBC cell lines 2 µM 24 hours Evaluate the effect of Sitravatinib combined with CDK4/6 inhibitors on TNBC cells, showing significant suppression of Met, Axl, and MerTK activities. PMC11202171

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice A375 BRAF-mutated melanoma xenografts Oral 45 mg/kg or 90 mg/kg Once a day for 56 days To assess the time course of abemaciclib-mediated target engagement and cell cycle arrest in A375 xenograft tumours, the model successfully described the concentration-dependent time course of pRb, TopoIIa, and pHH3. PMC4800303
mice 786-O cell orthotopic xenografts oral gavage 60 mg/kg twice daily for 25 days Abemaciclib suppressed the growth of 786-O xenograft tumors. PMC6913182
Mice PDX 14-07 Oral 90 mg/kg Once daily for 21 to 28 days To study the effect of Abemaciclib on the PDX 14-07 tumor model, results showed that Abemaciclib induced marked gains in H3K27ac. PMC8115221
Mice p16-3MR mice Intraperitoneal injection 50 mg/kg Once daily for 7 days Abemaciclib induced p16 expression and SA-β-gal activity in the kidneys of mice, indicating the induction of cellular senescence, but did not cause significant physical performance decline or changes in blood counts. PMC8922251
Mice H358 orthotopic lung cancer model Oral 10 mg/kg Once daily for three weeks To evaluate the inhibitory effect of Abemaciclib on the growth of H358 orthotopic lung tumors. Results showed that Abemaciclib alone slightly inhibited tumor growth, while the combination with P2shortA completely inhibited tumor growth. PMC7019173
Nude mice MDA-MB-231 and MCF7AR xenograft models Oral and intraperitoneal injection 100 mg/kg Three times a week To evaluate the inhibitory effect of combined treatment with Abemaciclib and Olaparib or LJI308 on tumor growth. The results showed that the combined treatment significantly inhibited tumor growth and induced apoptosis of tumor cells. PMC10687910
Mice MCF7 FAT1-loss xenograft model Intraperitoneal injection 25 mg/kg 3 consecutive days BSJ-05-017 significantly inhibited the activity of CDK4 and CDK6 and reduced the phosphorylation level of RB1. PMC8831444
Nude mice ST941-HI PDX model Oral 10 mg/kg Daily for 150 days To evaluate the anti-tumor activity of Abemaciclib in CDK4/6 inhibitor-resistant PDX models. Results showed that Abemaciclib caused significant tumor growth inhibition in models continuously exposed to Fulvestrant and Palbociclib, indicating that these tumors retain ER-dependent tumor growth despite prior CDK4/6 inhibitor treatment. PMC6921513

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04750928 Neurofibromatosis 1 PHASE1|PHASE2 RECRUITING 2029-12-31 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT02387814 Hepatic Insufficiency PHASE1 COMPLETED 2025-08-15 DaVita Clinical Research, Lake... More >>wood, Colorado, 80228, United States|Clinical Pharmacology of Miami (CPMI), Miami, Florida, 33014, United States|Orlando Clinical Research Center (OCRC), Orlando, Florida, 32809, United States|Indiana University - Digestive and Liver Diseases, Indianapolis, Indiana, 46202, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<
NCT03310879 Cancer PHASE2 RECRUITING 2026-04-30 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less <<
NCT03130439 Breast Cancer PHASE2 TERMINATED 2022-01-30 Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less <<
NCT02102490 Metastatic Breast Cancer PHASE2 COMPLETED 2018-10-22 Northern Arizona Hematology & ... More >>Oncology Associates, Sedona, Arizona, 86336, United States|HOPE Hematology Oncology Physicians and Extenders, Tucson, Arizona, 85704, United States|Arizona Clinical Research Center, Tucson, Arizona, 85715, United States|Univ of California San Francisco, San Francisco, California, 94115, United States|Sansum Medical Research Foundation, Santa Barbara, California, 93105, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80220, United States|Washington Hospital Center, Washington, District of Columbia, 20010, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916, United States|Advanced Medical Specialties, Miami, Florida, 33176, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, 21044, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, 55404, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, 45242, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Texas Oncology Cancer Center, Austin, Texas, 78731, United States|Texas Oncology - Bedford, Bedford, Texas, 76022, United States|Presbyterian Hospital Dallas, Dallas, Texas, 75231, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|Texas Oncology-Memorial City, Houston, Texas, 77024, United States|Texas Oncology-Plano West, Plano, Texas, 75093, United States|Texas Oncology-Sherman, Sherman, Texas, 75090-0504, United States|US Oncology, The Woodlands, Texas, 77380, United States|Tyler Cancer Center, Tyler, Texas, 75702, United States|Northwest Cancer Specialists PC, Vancouver, Washington, 98684, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, 1000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, 6000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, 3000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, 4000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, 21034, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, 75248, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, 08035, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, 28007, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, 46015, Spain Less <<
NCT03703466 Metastatic Breast Cancer PHASE2 COMPLETED 2023-03-09 Mater Private Hospital, North ... More >>Sydney, New South Wales, 2291, Australia|St Vincent's Hospital, Sydney, New South Wales, 2010, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, 5037, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, 3000, Belgium|Russian Oncological Research Center, Moscow, 115478, Russian Federation|Volgograd regional clinical oncology dispensary, Volgograd, 400138, Russian Federation|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, 08023, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Akdeniz University Medical Faculty, Antalya, 07058, Turkey|Trakya University Faculty of Medicine, Edirne, 22030, Turkey|Medical Park Izmir Hospital, Izmir, 35575, Turkey|Inonu University Medical Faculty, Malatya, 44280, Turkey Less <<
NCT03837821 Bladder Cancer EARLY_PHASE1 ACTIVE_NOT_RECRUITING 2025-12-25 Moffitt Cancer Center, Tampa, ... More >>Florida, 33612, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, 11217, United States|Weill Cornell Medicine, New York, New York, 10065, United States|UT Southwestern Medical Center - Simmons Comprehensive Cancer Center, Dallas, Texas, 75390, United States Less <<
NCT02482935 Healthy PHASE1 COMPLETED 2025-09-15 Covance Clinical Research Unit... More >>, Daytona Beach, Florida, 32117, United States|Covance Clinical Research Unit, Dallas, Texas, 75247, United States Less <<
NCT01739309 Mantle Cell Lymphoma PHASE2 COMPLETED 2022-09-05 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, 59037, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, 33604, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, 66421, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, 34125, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, 55131, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, 90419, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, 89081, Germany Less <<
NCT03763604 Metastatic Breast Cancer APPROVED_FOR_MARKETING - Liverpool Hospital, Liverpool,... More >> New South Wales, 2170, Australia|North West Cancer Centre, North Tamworth, New South Wales, 2340, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, 2010, Australia|Mater Hospital Sydney, Sydney, New South Wales, 2060, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Wollongong Hospital, Wollongong, New South Wales, 2500, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Adelaide Oncology and Haematology, Calvary Central Districts Hospital, Elizabeth Vale, South Australia, 5112, Australia|Icon Cancer Centre - Hobart, Hobart, Tasmania, 7000, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7001, Australia|Box Hill Hospital Outpatients, Box Hill, Victoria, 3128, Australia|Epworth Eastern Hospital, Box Hill, Victoria, 3128, Australia|Melbourne Cancer Care, Brighton, Victoria, 3186, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Dr. Zimet Private Room, Richmond, Victoria, 3121, Australia|Slade Pharmacy Epworth Hospital, Richmond, Victoria, 3121, Australia|Goulburn Valley Health, Shepparton, Victoria, 3630, Australia|Icon Cancer Care - The Wesley Medical Centre, Auchenflower, 4066, Australia|Northern Beaches Hospital, Freches Forest, 2086, Australia|South Coast District Hospital, Victor Harbor, 5211, Australia|Tom Baker Cancer Center, Calgary, Alberta, T2N4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|British Columbia Cancer Agency - Vancouver Island, Victoria, British Columbia, V8R 6V5, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, N2G 1G3, Canada|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Algoma District Cancer Program, Sault Ste. Marie, Ontario, P6B 0A8, Canada|Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada|CHUL du CHU de Québec, Québec City, Quebec, G1V 4G2, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada|Cairo Oncology Center (Cairo Cure), Mohandeseen, Cairo, 12655, Egypt|Apollo Cancer Institute, Apollo Speciality Hospital, Teynampet, Chennai, 600018, India|Indraprastha Apollo Hospital, New Delhi, 110076, India|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Torre, Roma, 00133, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, 35128, Italy|Ospedale Di Circolo E Fondazione Macchi, Varese, 21100, Italy|National Cancer Center, Ilsandong-gu, Goyang-si Gyeonggi-do, 10408, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Inha University Hospital, Incheon, Incheon-gwangyeoksi [Incheon], 22332, Korea, Republic of|St. Mary's Hospital, Gyeonggi-do, Korea, 11765, Korea, Republic of|Gachon University Gil Medical Center, Namdong-gu, Incheon, Korea, 21556, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, 06591, Korea, Republic of|National Cancer Center, Goyang-si, Kyǒnggi-do, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], 03722, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], 06351, Korea, Republic of|Ewha University Mokdong Hospital, Seoul, Yangcheon-gu, 07985, Korea, Republic of|Chungbuk National University Hospital, Chungcheongbuk-do, 28644, Korea, Republic of|Kyungpook National University Medical Center Chilgok Hospital, Daegu, 41404, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Pantai Hospital Sungai Petani, Sungai Petani, Kedah, 08000, Malaysia|Gleneagles Penang, Georgetown, Penang, 10050, Malaysia|Penang Adventist Hospital, Georgetown, Penang, 11350, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Penang, 11200, Malaysia|Beacon Hospital, Off Jalan Templer, Petaling JAYA, 46050, Malaysia|Pantai Hospital Penang, Bayan BARU, Pulau Pinang, 11900, Malaysia|Loh Guan Lye Specialists' Centre, Georgetown, Pulau Pinang, 10400, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, 93586, Malaysia|Subang Jaya Medical Centre, Petaling Jaya, Selangor, 47500, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, 59100, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, 50586, Malaysia|Universiti Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia|Institut Kanser Negara, Putrajaya, 62250, Malaysia|Elizabeth Au Oncology, Singapore, 228510, Singapore|Vincent Pallotti Hospital, Pinelands, Cape Town, 7405, South Africa|Flora Clinic, Floracliff, Gauteng, 1715, South Africa|Olivedale Clinic, Johannesburg, Gauteng, 2158, South Africa|Netcare Linksfield Hospital, Johannesburg, Gauteng, 2192, South Africa|Donald Gordon Medical Center, Johannesburg, Gauteng, 2193, South Africa|Wits Donald Gordon Clinical Trial Center, Johannesburg, Gauteng, 2193, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, 2196, South Africa|Sandton Oncology, Morningside, Gauteng, 2196, South Africa|DGMC Oncology, Parktown, Gauteng, 2193, South Africa|Amanzimtoti Oncology Centre, Durban, KwaZulu-Natal, 4126, South Africa|Hopelands Cancer Centre Hilton, Hilton, KZN, 3245, South Africa|Abraham Oncology, Richards Bay, KZN, 3900, South Africa|Cancercare, George, Western Cape, 7764, South Africa|Dr Pirjol and Szpak Inc. Oncology Pratice, Amanzimtoti, 4126, South Africa|Cancercare Rondebosch Oncology, Cape Town, 7700, South Africa|Hospital Virgen de los Lirios, Alcoy, Alicante, 03800, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Andalucía, 29010, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], 8035, Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Barcelona [Barcelona], 08915, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Barcelona, 17007, Spain|Hospital Duran I Reynals, Hospitalet De Llobregat, Barcelona, 08908, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital Germans Trias i Pujol, Badalona, Catalunya [Catalu?a], 08916, Spain|Hospital Universitario de Canarias, Tenerife, La Laguna, 38320, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital la Zarzuela, Aravaca, Madrid, 28023, Spain|Hospital De Mostoles, Mostoles, Madrid, 28935, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Palma De Mallorca(Baleares), 07120, Spain|H. San Francisco de Borja (H. GANDIA), Gandia, Valencia, 46702, Spain|Hospital Lluis Alcanyis, Xativa, Valencia, 46800, Spain|Hospital De Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital General de Albacete, Albacete, 02006, Spain|Hospital Quironsalud Barcelona- END, Barcelona, 08023, Spain|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, 08023, Spain|Hospital Universitari Dexeusa, Barcelona, 08028, Spain|Instituto Oncologico Dr Rosell (IOR), Barcelona, 08028, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Arquitecto Marcide (área Sanitaria de Ferrol), Coru?a, 15405, Spain|Hospital Universitario San Cecilio, Granada, 18016, Spain|Cl. Universitaria Navarra, Madrid, 28022, Spain|Centro Oncológico MD Anderson, Madrid, 28033, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Madrid Norte Sanchinarro, Madrid, 28050, Spain|Hospital Infanta Cristina, Madrid, 28981, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, 37007, Spain|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain|Hospital Clinico Universitario Valencia, Valencia, 46010, Spain|Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain|Hospital Arnau de Vilanova Valencia, Valencia, 46015, Spain|Hospital Doctor Peset, Valencia, 46017, Spain|Hospital de Sagunto, Valencia, 46500, Spain|IDCQ HOSPITALES Y SANIDAD, S.L.U. (Hospital Quirón Zaragoza), Zaragoza, 50006, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Hospital Universitario Zaragoza, Zaragoza, 50009, Spain|Universit?tsspital Basel, Basel, Basel Stadt, 4031, Switzerland|H?pital de la Tour, La Tour H?pital Privé SA, Meyrin, Geneva, 1217, Switzerland|Tumorzentrum ZeTuP Rapperswil-Jona, Rapperswil, Saint Gallen, 8640, Switzerland|Tumor- und Brustzentrum ZeTuP Sankt Gallen, St. Gallen, Saint Gallen, 9000, Switzerland|Cantonal Hospital St.Gallen, st.Gallen, Sankt Gallen, 9007, Switzerland|Oncologia Varini Calderoni Christinat, Lugano, Ticino, 6900, Switzerland|H?pitaux Universitaires de Genève, Geneva, 1205, Switzerland|HUG-H?pitaux Universitaires de Genève, Genève, 1211, Switzerland|Luzerner Kantonsspital, Luzern, 6000, Switzerland|OnkoZentrum Zürich AG, Zürich, 8038, Switzerland|Chiayi Chang Gung Memorial Hospital, Putzu City, Chiayi County, 61363, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Niaosong Dist, Kaohsiung City, 833, Taiwan|Tri-Service General Hospital, Taipei City, Taipei, 114, Taiwan|National Taiwan University Hospital Yunlin Branch, Zhongzheng District, Taipei, 10048, Taiwan|MacKay Memorial Hospital, New Taipei City, Tamsui District, 251, Taiwan|Taichung Tzu Chi Hospital, Taichung, Tanzi District, 427, Taiwan|Saint Paul's Hospital, Taoyuan, Taoyuan District, 330, Taiwan|Kaohsiung Municipal Siaogang Hospital, Kaohsiung City, 812, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 40705, Taiwan|Taipei Veterans General Hospital, Taipei City, 11217, Taiwan|National Taiwan University Hospital, Taipei, 100229, Taiwan|Mackay Memorial Hospital, Taipei, 10449, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Koo Foundation Sun Yan-Sen Cancer Center, Taipei, 112, Taiwan|National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City, 64041, Taiwan|Maharaj Nakorn Chiang Mai Hospital, Muang Chiangmai, Chiangmai, 50200, Thailand|Rajavithi Hospital, Bangkok, Ratchathewi District, 10400, Thailand|Songklanagarind Hospital, Hat Yai, Songkhla, 90110, Thailand|King Chulalongkorn Memoiral Hospsital, Bangkok, 10330, Thailand|Ramathibodi Hopsital, Bangkok, 10400, Thailand|Addenbrookes Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Loom Dene, Radlett, Hertfordshire, WD7 8AA, United Kingdom|Northern Centre for Cancer Treatment, Newcastle Upon Tyne, Tyne And Wear, NE7 7DN, United Kingdom Less <<
NCT02919696 Advanced Cancer|Metastatic Can... More >>cer Less << PHASE1 COMPLETED 2019-09-03 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changsha, 410013, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, 200030, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China Less <<
NCT04003896 Biliary Tract Carcinoma PHASE2 TERMINATED 2023-08-15 Penn State Cancer Institute, H... More >>ershey, Pennsylvania, 17033-0850, United States Less <<
NCT04408924 Metastatic Castration-Resistan... More >>t Prostate Cancer Less << PHASE2 COMPLETED 2023-06-02 University of Utah - Huntsman ... More >>Cancer Institute, Salt Lake City, Utah, 84112, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Centre Leon Berard, Lyon Cedex 08, 69373, France|Institut Paoli-Calmettes, Marseille, 13273, France|Hopital Europeen Georges Pompidou, Paris, 75015, France|Institut Claudius Regaud, Toulouse cedex 9, 31059, France|Gustave Roussy, Villejuif Cedex, 94805, France|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain Less <<
NCT04681768 Breast Cancer/ Metastatic Brea... More >>st Cancer Less << RECRUITING 2025-12-24 Klinikum rechts der Isar der T... More >>U München, Klinik und Poliklinik für Frauenheilkunde, Munich, 81675, Germany Less <<
NCT04169074 HNSCC PHASE2 RECRUITING 2025-06-30 University of Arizona, Tucson,... More >> Arizona, 85719, United States Less <<
NCT04941274 Kaposi Sarcoma PHASE1|PHASE2 RECRUITING 2028-06-01 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT02644460 Diffuse Intrinsic Pontine Glio... More >>ma|Brain Tumor, Recurrent|Solid Tumor, Recurrent|Neuroblastoma, Recurrent, Refractory|Ewing Sarcoma, Recurrent, Refractory|Rhabdomyosarcoma, Recurrent, Refractory|Osteosarcoma, Recurrent, Refractory|Rhabdoid Tumor, Recurrent, Refractory Less << PHASE1 COMPLETED 2023-10-10 Phoenix Children's Hospital, P... More >>hoenix, Arizona, 85016, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Children's Healthcare of Atlanta, Egleston, Atlanta, Georgia, 30322, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, 30342, United States Less <<
NCT03356587 HNSCC|Head and Neck Neoplasms PHASE2 UNKNOWN 2020-12-31 Seoul National University Hosp... More >>ital, Seoul, 110-744, Korea, Republic of Less <<
NCT04040205 Chondrosarcoma|Osteosarcoma|So... More >>ft Tissue Sarcoma Less << PHASE2 RECRUITING 2026-06-01 Mayo Clinic, Jacksonville, Flo... More >>rida, 32224, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|Washington University in St. Louis, Saint Louis, Missouri, 63130, United States|Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT02831530 Breast Cancer PHASE2 COMPLETED 2018-02-02 Gustave Roussy, Villejuif, Val... More >> De Marne, 94805, France Less <<
NCT06678269 Metastatic Breast Cancer|Stage... More >> IV Breast Cancer|Breast Cancer|Breast Cancer Stage IV|Breast Cancer Metastatic|HER2-negative Breast Cancer|HER2 Negative Breast Carcinoma|Hormone-receptor-positive Breast Cancer Less << PHASE1 RECRUITING 2028-11-30 Memorial Sloan Kettering at Ba... More >>sking Ridge (All protocol activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, 11553, United States Less <<
NCT02792725 Metastatic Breast Cancer APPROVED_FOR_MARKETING - Pacific Cancer Care, Monterey,... More >> California, 93940, United States|UCLA Medical Center, Santa Monica, California, 90404, United States|Orlando Health, Inc, Orlando, Florida, 32806, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Minnesota Medical Center, Fairview Lakes, Wyoming, Minnesota, 55092, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, 64111, United States|Memorial Sloan Kettering Cancer Center, Commack, New York, 11725, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|West Virginia University Hospital, Morgantown, West Virginia, 26506, United States Less <<
NCT02846987 Sarcoma|Dedifferentiated Lipos... More >>arcoma Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-07-25 Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less <<
NCT03356223 Head and Neck Cancer|Advanced ... More >>Cancer|Metastatic Cancer Less << PHASE2 COMPLETED 2022-12-05 H?pital Saint-André, Bordeaux,... More >> 33075, France|Centre Léon Bérard, Lyon, 69373, France|Centre Antoine Lassagne, Nice, 06189, France Less <<
NCT03891784 Advanced Digestive System Neur... More >>oendocrine Neoplasm|Digestive System Neuroendocrine Tumor|Foregut Neuroendocrine Tumor|Hindgut Neuroendocrine Tumor|Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm|Metastatic Digestive System Neuroendocrine Neoplasm|Midgut Neuroendocrine Tumor|Pancreatic Neuroendocrine Tumor|Refractory Digestive System Neuroendocrine Neoplasm Less << PHASE2 ACTIVE_NOT_RECRUITING 2026-09-30 University of Colorado, Denver... More >>, Colorado, 80217, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States Less <<
NCT03339843 Esophageal Adenocarcinoma|Esop... More >>hagus SCC|Cholangiocarcinoma|Urothelial/Bladder Cancer, Nos|Endometrial Cancer Less << PHASE2 COMPLETED 2023-12-20 Universitair Ziekenhuis, Antwe... More >>rpen, Belgium|Institut Jules Bordet, Bruxelles, 1000, Belgium|Algemeen Ziekenhuis Groeninge, Kortrijk, 8500, Belgium|CHC Saint-Joseph, Liège, 4000, Belgium|CHU Ambroise Paré, Mons, 7000, Belgium|CHU UCL Namur Sainte-Elisabeth, Namur, 5000, Belgium|Centre Oscar Lambret, Lille, 59000, France|Institut Paoli-Calmettes, Marseille, 13009, France|Centre Henri Becquerel, Rouen, 76038, France|H?pital universitaire de Strasbourg - ICANS, Strasbourg, 67000, France|IUCT Oncopole - Institut Claudius Regaud, Toulouse, 31059, France Less <<
NCT04552769 Thyroid Cancer|Anaplastic Thyr... More >>oid Cancer|Undifferentiated Thyroid Cancer Less << PHASE2 ACTIVE_NOT_RECRUITING 2024-12-31 Stanford University, Stanford,... More >> California, 94305, United States Less <<
NCT02308020 Breast Cancer|Non-small Cell L... More >>ung Cancer|Melanoma|Brain Metastases Less << PHASE2 COMPLETED 2019-11-08 City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|University of California - San Diego, La Jolla, California, 92037-0845, United States|Univ of California San Francisco, San Francisco, California, 94115, United States|John Wayne Cancer Institute, Santa Monica, California, 90404, United States|University of Colorado, Aurora, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916-2233, United States|H Lee Moffitt Cancer Center, Tampa, Florida, 33612-9497, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, 96819, United States|James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Washington University Medical Center, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Providence Health and Services, Portland, Oregon, 97213, United States|SMO Sarah Cannon Research Inst., Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, 6009, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, 2298, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southport, 4215, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, 4102, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, 1090, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, 1000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, 6000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, 3000, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, 4000, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, K1H 8L6, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille Cedex, 59020, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, 59037, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon Cedex 08, 69373, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris Cedex 05, 75248, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint-Brieuc, 22027, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse cedex 9, 31059, France|Hadassah Medical Center - Ein Karem, Jerusalem, 9112001, Israel|Sheba Medical Center, Tel Hashomer, 5265601, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cona, 44124, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, 16132, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, 35128, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, 00128, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, 08035, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, 28034, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, 41013, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.87mL

1.97mL

0.99mL

19.74mL

3.95mL

1.97mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories